Constellation Alpha Capital Corp
Constellation Alpha Capital — SPAC Merger (May 2019)
25 slides from Constellation Alpha Capital's SPAC merger presentation, May 29, 2019
Slide 1: Constellation Alpha Capital Corp merger with DermTech, Inc.
Constellation Alpha Capital Corp merger with DermTech, Inc.
Slide 2: Disclaimer
Disclaimer This presentation (this “Presentation”) is for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination between DermTech, Inc. (“Target”) and Constellation Alpha Capital Corp. (“CNAC”) an
Slide 3: Transaction Summary
Transaction Summary • Constellation Alpha Capital Corp. (“CNAC”) is a NASDAQ listed Special Purpose Acquisition Company • DermTech Inc. is a San Diego based molecular genomics company, with an initial focus on skin cancer, that develops and markets novel non - invasive diagnostic tests • DermTech wi
Slide 4: Transaction Terms and Structure
Transaction Terms and Structure • Existing DermTech investors will roll 100% of their equity ownership into the pro forma Company at a price of $3.25 per common share • Investors will execute PIPE subscription agreements for $20 million at a price of $3.25 per common share PRO FORMA OWNERSHIP ( a )
Slide 5: Investment Rationale
Investment Rationale Disruptive Change • DermTech is an adhesive patch instead of a surgical incision • Likelihood of missed melanoma: 1% for PLA test vs 17% for current standard (surgical biopsy) • ~6x cost saving per melanoma detected vs surgical biopsy • ~15M surgical biopsies to diagnose 5.4M ca
Slide 6: Management Team
Management Team Name Title Background Dr. John Dobak Chief Executive Officer • Founder & Chairman of 10xBio (aesthetic medicine drugs) • Chairman Pantherics (anti - inflammatory drugs) • Former Founder/ CEO of CryoCor/CryoGen and InnerCool Therapies. • MD, UCSD. Bachelors, UCLA. Todd Wood Chief Comm
Slide 7: Board of Directors
Board of Directors Gary Jacobs, Chairman of Board • Chairman of the Board since June 2006, Senior Executive Qualcomm, active life science investor Matt Posard, Board Member • Former Head of Global Sales and General Management Illumina, Biosite, Trovagene Cynthia Collins, Board Member • CEO Editas Me
Slide 8: Genomic Innovators are Disrupting the Diagnostic Testing Market
Genomic Innovators are Disrupting the Diagnostic Testing Market • 44% share of non - hospital dx revenue • ~$ 19 billion in revenue • ~$24 billion in market cap • ~(20)% 2018 stock return • ~1.7x implied EV / revenue multiple • <5% market share • ~$1 billion in revenue • ~$15 billion in market cap •
Slide 9: Breakthrough Non-Invasive Test vs. Unnecessary Surgery
Not Skin Cancer Skin Cancer 3+ million biopsies to detect ~0.15 million cases of melanoma Pigmented Lesion Assessment for Melanoma (PLA) Source: American Cancer Society, Cancer Facts & Figures 2018 DERMATOLOGISTS CUT TO BE “SAFE” BREAKTHROUGH NON - INVASIVE TEST • Clinicians – Payment for Test – Eas
Slide 10: DermTech Adhesive Skin Collection Box & Report
DermTech Adhesive Skin Collection Box & Report DermTech Adhesive Skin Collection Kit contains all necessary materials to non - invasively collect and mail a skin sample to the DermTech Laboratory for molecular pathology gene expression analysis. PLA Report provides simple POSITIVE/NEGATIVE read - ou
Slide 11: Milestones: PLA Test
Milestones: PLA Test Source: DermTech, Inc. Issued US Patents provide protection until 2034 • Broad methods for RNA analysis of skin collected by adhesive patch • Method of detection of biological factors in epidermis • Broad claims for melanoma gene classifier • Patents issued in multiple European
Slide 12: PLA Test Outperforms Surgical Biopsy
PLA Test Outperforms Surgical Biopsy PERFORMANCE METRIC SURGICAL BIOPSY PLA TEST IMPROVEMENT Probability of missed melanoma 17% 1% 17x Surgery needed per melanoma detected 25 - 30 2.7 10x Cost per melanoma detected $23,675 $3,780 6x Sources: JAMA Dermatology, 2018, doi:10.1001/jamadermatol.2018.0212
Slide 13: PLA Test: Significant Clinical Validation
PLA Test: Significant Clinical Validation MILESTONE STATUS SAMPLE SIZE Analytical Validation ط Complete 125 Clinical Validation – pathology ط Complete 555 Clinical Validation – mutation ط Complete 626 Clinical Utility ط Complete 45 Derms Real World Utility ط Complete 381 1 - Year Follow - Up ط Compl
Slide 14: PLA: MolDX Coverage, Consensus Recommendations, AAD Guidelines, Top KOLs
PLA: MolDX Coverage, Consensus Recommendations, AAD Guidelines, Top KOL’s Source: DermTech, Inc. MOLDX, AAD MELANOMA GUIDELINES & EXPERT PANEL RECOMMENDATIONS KEY MEDICAL SOCIETY ENDORSEMENTS RESPECTED PHYSICIAN VALIDATION • American Academy of Dermatology • Society of Investigative Dermatology • Am
Slide 15: Cancer Detection Breakthrough - Case Study
Cancer Detection Breakthrough - Case Study • 28 y.o. female • Family history of melanoma • Complained of bug bite • Refused surgical biopsy • PLA + • Histopathology 0.5 mm amelanotic melanoma • Case study published in JAMA Dermatology 16
Slide 16: DermTech Product Pipeline
DermTech Product Pipeline PRODUCT TEST PURPOSE ASSAY TYPE GENE TARGETS MARKETED PLA Melanoma R/O PCR LINC, PRAME Yes Nevome Melanoma R/I Mut BRAF, NRAS, TERT Yes Carcinome Basal/Squam R/O PCR Not Disclosed In Progress TBD Inflammatory Disease Treatment/Dx PCR Th1, Th2, Th17 In Progress Rejuvome Skin
Slide 17: Commercialization Plan
Commercialization Plan Payer Coverage Decision • Build payer Access team • Medicare MolDX coverage • Major payers coverage (United, Aetna, Cigna, Humana, etc.) Direct Physician Sales • Todd Wood, CCO - Former Allergan Head of Derm and Ophtho Sales • Grow to 65 person sales team over 3 years. Distrib
Slide 18: The Dermatology Practice Market Favors Rapid Adoption
The Dermatology Practice Market Favors Rapid Adoption 29% 18% 26% 14% 8% 5% 1 2 3 to 5 6 to 10 11 to 25 26+ 45% 15% 17% 23% 1 to 50 51 to 75 76 to 100 100+ 45% 43% 10% 2% Access Anytime Call for Appointment No Access Unknown Dermatologist Daily Patient Volume Physician Access Number of Doctors per O
Slide 19: Commercialization Plan: Dermatology
Commercialization Plan: Dermatology Source: DermTech, Inc. SALES • Expand Dermatology Sales Force H2 2019 after CMS Approval – 22 reps end of 2019 growing to 75 rep by end of 2022 – Targeting 2 - 3 new physician accounts per rep per month • Out 12,000+ Total US Derm Practice Professionals ~50% penet
Slide 20: Anticipated Ramp-Up Post CMS Approval: Dermatology PLA Sales
- 50,000 100,000 150,000 200,000 250,000 300,000 350,000 $- $20,000,000 $40,000,000 $60,000,000 $80,000,000 $100,000,000 $120,000,000 $140,000,000 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 Monhts Sample Volume and Revenue Post Medicare Appr
Slide 21: Estimated Revenue: Dermatology PLA Sales
Estimated Revenue: Dermatology PLA Sales Source: Capital IQ for Exact Sciences, market capitalization values as of end of year 2016, 2017 and 2018. Management estimat es for DermTech, Inc. Pre - CMS Post - CMS 2014: $1.8M 2015: $39M 2017: $266M 2016: $99M 2018: $2.6M Year 1 $15M Year 3 $100M+ Year 2
Slide 22: Select Listed Comparables
Select Listed Comparables Source: Capital IQ, as of 3/19/2019. All future estimates per Wall Street Research consensus model via Capital IQ. (a) “NM” denotes multiples less than 0.0x or greater than 30.0x. COMPANY TICKER MARKET CAP CASH ON HAND EV FY19E SALES FY20E SALES FY19E EBITDA FY20E EBITDA EV
Slide 23: Backup Slides
BACKUP SLIDES
Slide 24: Superior Performance and Cost Savings for Payers
Surgical Biopsy (100%) NEGATIVE 61% MELANOMA 5% ATYPIA+ margin 34% 17% Probability of Missed Melanoma Narrow Excision 21% Wide Excision 5% 26% of All Lesions Excised Clinical Atypia Surgical Biopsy 12% Melanoma 5% Adhesive Patch Sample NEGATIVE 88% POSITIVE 12% Atypia+ Margins 6% Narrow Excision 3%
Slide 25: Benefits Across Value Chain
PHYSICIANS PAYORS PATIENTS • Reduces missed melanoma addressing the greatest concern in dermatology • Opportunity to enhance practice revenue • Improved patient satisfaction by avoiding surgery and scarring • Improve patient flow and throughput • Favorable practice economics • Fewer surgical costs a